Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort demographic, clinical, and laboratory features

Basit Öğe Kaydı
dc.contributor.authorAltintas A.
dc.contributor.authorKarabudak R.
dc.contributor.authorBalca B.P.
dc.contributor.authorTerzi M.
dc.contributor.authorSoysal A.
dc.contributor.authorSaip S.
dc.contributor.authorKurne A.T.
dc.contributor.authorUygunoglu U.
dc.contributor.authorNalbantoglu M.
dc.contributor.authorCelik G.G.
dc.contributor.authorIsik N.
dc.contributor.authorCelik Y.
dc.contributor.authorGokcay F.
dc.contributor.authorDuman T.
dc.contributor.authorBoz C.
dc.contributor.authorYucesan C.
dc.contributor.authorMangan M.S.
dc.contributor.authorCelebisoy N.
dc.contributor.authorDiker S.
dc.contributor.authorIsikay I.C.
dc.contributor.authorKansu T.
dc.contributor.authorSiva A.
dc.date.accessioned2019-10-26T21:26:59Z
dc.date.available2019-10-26T21:26:59Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. Objective: To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. Methods: A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Results: Mean age was 38.43 ± 12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29 ± 12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Conclusion: Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or lateonset NMO, and no correlation between disability and NMO IgG status. © 2015 Wolters Kluwer Health, Inc. All rights reserved.en_US
dc.identifier.doi10.1097/NRL.0000000000000057en_US
dc.identifier.endpage66en_US
dc.identifier.issn1074-7931
dc.identifier.issue4en_US
dc.identifier.pmid26468870en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage61en_US
dc.identifier.urihttps://doi.org/10.1097/NRL.0000000000000057
dc.identifier.urihttps://hdl.handle.net/11454/17385
dc.identifier.volume20en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams and Wilkinsen_US
dc.relation.ispartofNeurologisten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAquaporin-4 antibodyen_US
dc.subjectClinical findingsen_US
dc.subjectLate onseten_US
dc.subjectNeuromyelitis opticaen_US
dc.subjectNeuromyelitis optica spectrum disorderen_US
dc.subjectPrognosisen_US
dc.titleNeuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort demographic, clinical, and laboratory featuresen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu